Cassava Sciences’ Legal Victory Clears Research Path
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cassava Sciences ( (SAVA) ).
On October 23, 2025, the United States District Court for the District of Maryland dismissed the criminal indictment against Dr. Hoau-Yan Wang, a former scientific collaborator with Cassava Sciences. The charges, which included allegations of falsifying research for grant applications, were permanently terminated, allowing Cassava to continue its research efforts without the shadow of legal proceedings, thereby reinforcing its commitment to scientific integrity.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences is a company focused on the pharmaceutical industry, primarily engaged in the development of investigational drugs. The company is currently evaluating simufilam as a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy, based on research conducted at various institutions.
Average Trading Volume: 2,542,424
Technical Sentiment Signal: Sell
Current Market Cap: $178.7M
Find detailed analytics on SAVA stock on TipRanks’ Stock Analysis page.
